phase-i-trial

Novo Nordisk

Novo Nordisk Rocketing to Success with Breakthrough Obesity Drug - Amycretin

Novo Nordisk's oral weight-loss drug, Amycretin, is causing waves with a 13.1% weight loss in early trials! ๐Ÿš€ #NovoNordisk #Amycretin #WeightLoss

See more